N
IOVA icon

Natixis’s Iovance Biotherapeutics IOVA Stock Holding History

Natixis’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,503
Closed -$26.3K – 1265
2026
Q1 		$26.3K Buy
+7,503
New +$24K ﹤0.01% 1001
2025
Q4 		– Sell
-20,479
Closed -$44.4K – 1215
2025
Q3 		$44.4K Sell
20,479
-23,801
-54% -$56.2K ﹤0.01% 940
2025
Q2 		$76.2K Buy
+44,280
New +$110K ﹤0.01% 852
2023
Q3 		– Sell
-15,989
Closed -$113K – 1063
2023
Q2 		$113K Buy
15,989
+14,949
+1,437% +$107K ﹤0.01% 790
2023
Q1 		$6.35K Hold
1,040
– – ﹤0.01% 908
2022
Q4 		$6.65K Buy
+1,040
New +$8.12K ﹤0.01% 1013
2022
Q2 		– Sell
-143,040
Closed -$2.38M – 1254
2022
Q1 		$2.38M Buy
+143,040
New +$2.21M 0.01% 714
2021
Q3 		– Sell
-11,131
Closed -$290K – 1242
2021
Q2 		$290K Buy
+11,131
New +$289K ﹤0.01% 787

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Natixis's IOVA Position: Q2 2026 in Review

Natixis sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 7,503 shares — an estimated $26.3K sold.

Natixis first reported a position in IOVA in Q2 2021 and held it in 8 quarters. The position peaked at $2.38M in Q1 2022. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Natixis reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Natixis sold 7,503 Iovance Biotherapeutics shares in Q2 2026, an estimated $26.3K.
  • Natixis first reported a position in Iovance Biotherapeutics in Q2 2021 and held it in 8 quarters.
  • Natixis's Iovance Biotherapeutics position peaked at $2.38M in Q1 2022.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.